Q-omics provides the consensus-scored UTP14A profile across patient tissues and cancer cell-line models. UTP14A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, UTP14A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, UTP14A protein abundance shows 29,380 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where UTP14A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UTP14A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UTP14A survival associations across molecular data types. UTP14A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UTP14A RNA expression–survival associations across cancer types. High UTP14A expression shows unfavorable associations in KIRP, HNSC, UCEC, MESO and PAAD, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for UTP14A RNA expression.
This table summarizes UTP14A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UTP14A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UTP14A shows higher tumor expression in HNSC, COAD, KIRC, LIHC, STAD and LUSC. The HNSC box plot shows higher UTP14A RNA expression in tumor versus normal tissue (log2 FC = +1.194, t-test p < 0.001).
This table shows molecular features associated with UTP14A in patient tissues and cancer cell lines. In patient samples, UTP14A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UTP14A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
